Parisi Christina E, Gracy Hannah R, Bush Nicholas J, Cook Robert L, Wang Yan, Chichetto Natalie
Department of Epidemiology, University of Florida, Gainesville, Florida, USA.
Southern HIV and Alcohol Research Consortium, Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
Alcohol Clin Exp Res (Hoboken). 2023 Oct;47(10):1917-1925. doi: 10.1111/acer.15165. Epub 2023 Aug 28.
Many women living with HIV (WLWH) experience pain. Alcohol use with the intent to treat pain could lead to hazardous drinking and difficulty in reducing drinking. Naltrexone acts on opioid receptors important for pain regulation and is an approved treatment for alcohol use disorder. In this secondary analysis of a randomized double-blind placebo-controlled naltrexone clinical trial, the goals were to (1) compare alcohol reduction between women who drank to treat pain and those who did not and (2) examine differences in alcohol reduction by both drinking intention and treatment arm.
Women living with HIV (N = 194, mean age 48.3 years, 83% non-Hispanic Black, 11% Hispanic) with hazardous drinking (>7 drinks/week) were randomized to receive daily treatment with naltrexone 50 mg or placebo for 4 months. Study visits occurred at baseline and 2, 4, and 7 months (posttreatment). The number of drinks/week was measured using the Timeline Follow Back. Use of alcohol to treat pain was self-reported. Participants were categorized as using alcohol to treat pain or not and in the naltrexone or placebo group. Chi-square, t-test, MANOVA, and sequential mixed effects models were used to determine group differences in demographic factors, mean/drinks per week, and percent change in mean drinks/week at baseline and each follow-up visit.
There was a consistent decrease in drinking throughout the study. There was not a significant difference in mean drinks/week at any point in the study between women who used alcohol to treat pain and those who did not. When considering treatment arm, at 2 months only those who did not use alcohol to treat pain in the naltrexone group had a significantly lower mean drinks/week than the other groups (p = 0.007); all groups had similar decreases in drinking from 4 months onward.
In the naltrexone group, WLWH who drank to treat pain reduced their alcohol consumption more slowly than WLWH who did not drink to treat pain. Replication of these findings would suggest that alcohol treatment guidelines should address pain as a factor in drinking outcomes.
许多感染艾滋病毒的女性(WLWH)会经历疼痛。为缓解疼痛而饮酒可能会导致危险饮酒行为以及戒酒困难。纳曲酮作用于对疼痛调节至关重要的阿片受体,是一种获批用于治疗酒精使用障碍的药物。在这项对纳曲酮随机双盲安慰剂对照临床试验的二次分析中,目标是:(1)比较为缓解疼痛而饮酒的女性与不为此目的饮酒的女性在减少饮酒量方面的差异;(2)研究饮酒意图和治疗组对减少饮酒量的影响差异。
有危险饮酒行为(每周饮酒超过7杯)的感染艾滋病毒的女性(N = 194,平均年龄48.3岁,83%为非西班牙裔黑人,11%为西班牙裔)被随机分配,接受为期4个月的每日50毫克纳曲酮或安慰剂治疗。研究访视分别在基线、第2、4和7个月(治疗后)进行。每周饮酒量通过时间线追溯法进行测量。是否为缓解疼痛而饮酒通过自我报告确定。参与者被分为为缓解疼痛而饮酒或不为此目的饮酒的两类,且分别处于纳曲酮组或安慰剂组。采用卡方检验、t检验、多变量方差分析和序贯混合效应模型来确定不同组在人口统计学因素、每周平均饮酒量以及基线和每次随访时每周平均饮酒量变化百分比方面的差异。
在整个研究过程中饮酒量持续下降。在研究的任何时间点,为缓解疼痛而饮酒的女性与不为此目的饮酒的女性在每周平均饮酒量上均无显著差异。考虑治疗组时,仅在第2个月,纳曲酮组中不为缓解疼痛而饮酒的女性每周平均饮酒量显著低于其他组(p = 0.007);从第4个月起,所有组的饮酒量下降情况相似。
在纳曲酮组中,为缓解疼痛而饮酒的感染艾滋病毒女性比不为此目的饮酒的女性减少酒精摄入量的速度更慢。这些研究结果若能得到重复验证,则表明酒精治疗指南应将疼痛视为影响饮酒结果的一个因素。